 CAMBRIDGE, Mass.--BUSINESS WIRE--VBI Vaccines Inc. Nasdaq: VBIV VBI, a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today reported financial results for the second quarter ending June 30, 2021 and provided a corporate update. Jeff Baxter, VBIs President and CEO commented: The second quarter of 2021 was a data-rich period for the Company, with positive results across our lead programs, leading to meaningful advancement of 